Kiptembur

TESTED POSITIVE FOR CRITICAL THINKING

[Pharmacy and Poisons @ppbkenya]

WHO WE ARE!
@ppbkenya is Kenya’s National Regulatory Authority for for Health Products, Technologies (HPTs) and Pharmacy Practice

[Pharmacy and Poisons @ppbkenya]

How does the Directorate of Pharmacy Practice protect public health? Director of Pharmacy Practice, Dr. Wilfred Ochieng, explains the Directorate’s role in regulating pharmacy practice and safeguarding patients through quality pharmaceutical services.

[Pharmacy and Poisons @ppbkenya]

The PPB in collaboration with Pharmaceutical Society of Kenya, invites you to a webinar on:

📝 *United for Patient Safety: Understanding Recalls of HPTs*

📅 Date: Thursday, 9th July 2026

🕖 Time: 7:00 PM EAT

🔗 Register here: https://t.co/xiVPztGKnC

#PSK2026

[Pharmacy and Poisons @ppbkenya]

PPB Clarifies Facts on Parallel Imported Medicinal Products

[Pharmacy and Poisons @ppbkenya]

Kenya’s pharmaceutical sector continues to grow.

📈 Registered pharmaceutical premises have increased by 53%, from 6,852 in 2018 to 10,497 (as of 23 June 2026).

👩🏽‍⚕️ Licensed pharmacy professionals have grown by 70%, from 9,031 to 15,397, strengthening access to safe, quality and effective pharmaceutical services.

These milestones were highlighted during the PPB Regulatory Engagement Forum at the 46th Pharmaceutical Society of Kenya Annual Scientific Conference.

[MedLearn Hub @MedLearnHub]

✓ Procyclidine- It is an anticholinergic medication that works by blocking central acetylcholine receptors to restore dopamine-acetylcholine balance.
∆ Clinical uses-:
• It treats all forms of parkinsonism by effectively reducing disabling muscle rigidity, tremors, and bradykinesia.
• It is a frontline drug used to manage extrapyramidal symptoms like acute dystonia and akathisia caused by neuroleptics.
• The drug additionally helps control sialorrhea (excessive drooling) secondary to antipsychotic therapy.

[Pharmacy and Poisons @ppbkenya]

The Pharmacy and Poisons Board (PPB) has made significant strides towards attaining the World Health Organization’s Maturity Level 3 (ML3) status, a globally recognised benchmark that affirms the strength, credibility and performance of national medicines regulatory authorities.

Speaking during a panel discussion on “Balancing Regulatory Maturity with Business Continuity, Investor Confidence and Market Access,” Director of Pharmacy Practice Dr. Wilfred Ochieng said attaining ML3 reflects a stable, predictable and well-performing regulatory system that is trusted by international counterparts and supports access to quality, safe and effective medical products.

He noted that the ML3 framework is founded on key regulatory principles including consistency, independence, impartiality, clarity, proportionality and transparency, which are essential for effective regulation and fostering confidence among investors, manufacturers and the public.

Dr. Ochieng added that PPB is using the ML3 journey to strengthen institutional capacity through strategic investments in human resources, digital systems, operational efficiency and transparency, while continuously improving regulatory performance and service delivery.

#PSK46

[Pharmacy and Poisons @ppbkenya]

Strengthening collaboration across the health products and technologies value chain is essential to safeguarding patient safety while fostering innovation.

A panel discussion sponsored by the Kenya Association of Pharmaceutical Industry (KAPI) at the 46th Pharmaceutical Society of Kenya Annual Scientific Conference explored the role of collaboration in strengthening regulatory systems, promoting responsible innovation and reinforcing the integrity of pharmaceutical supply chains to ensure the continued availability of safe, quality and effective health products.

The panel featured Dr. James Oigo Mokoro, Chairperson, KAPI; Dr. John Mwangi, Board Member, KAPI; Stephen Wanyoke Mirara, Board Member, KAPI; and Dr. Janki Chauhan, Chairperson, MEDAK. The session was moderated by Dr. Stella Kiptanui, Executive Director, KAPI.

[Pharmacy and Poisons @ppbkenya]

Strengthening collaboration between the Pharmacy and Poisons Board and pharmaceutical stakeholders is essential to advancing patient safety, regulatory excellence and access to safe, quality and effective health products.

The Pharmacy and Poisons Board today convened the Regulator Engagement Forum during the 46th Pharmaceutical Society of Kenya Annual Scientific Conference, bringing together pharmaceutical stakeholders to discuss key regulatory priorities, including pharmacy practice, product registration, post-market surveillance, pharmacovigilance and the Board’s journey towards attaining WHO Maturity Level 3.

Representing the Board of Directors, Dr Isha Anand underscored the importance of sustained collaboration between the Board and stakeholders in strengthening regulatory systems and safeguarding public health.

The panel featured Dr Wilfred Ochieng, Dr Paulyne Wairimu, Dr Edward Abwao, Dr Jonathan Mariakol and Dr Christabel Kheamba, who shared insights on strengthening Kenya’s pharmaceutical regulatory landscape.

[Pharmacy and Poisons @ppbkenya]

The 46th Pharmaceutical Society of Kenya Annual Scientific Conference continues to provide an important platform for dialogue on emerging regulatory developments shaping Kenya’s pharmaceutical sector.

Speaking during a breakout session on “Regulatory Developments in the Market in Kenya from a Regulatory Standpoint: Trends and Opportunities,” Deputy Director, Product Safety, Dr. Christabel Khaemba highlighted the evolution of regulatory affairs from a function focused mainly on product registration to a strategic discipline that oversees the entire lifecycle of medical products.

Dr. Khaemba noted that market authorization is no longer the final step in regulation, emphasizing that continuous monitoring of the safety and effectiveness of medicines through pharmacovigilance is now central to protecting patients and ensuring health products continue to deliver their intended benefits throughout their use.

She outlined key regulatory milestones achieved by Kenya, including the adoption of risk-based regulatory approaches, application of regional and international reliance mechanisms, digitalization of regulatory systems, strengthened oversight of local health products manufacturing, and enhanced pharmacovigilance systems. These advances, she said, have improved regulatory efficiency, strengthened the quality, safety and effectiveness of health products, and enhanced the country’s readiness to regulate emerging health technologies.

Dr. Khaemba called on stakeholders to strengthen local pharmaceutical manufacturing, expand access to quality-assured medicines and position Kenya as a competitive regional regulatory hub as the Africa Medicines Agency becomes operational.
@PSofKenya

[ᴅᴇɴɴʏ ᴍɢ  @dennymwangi]

Ward round scenes should be recorded and documented 😂😂😂

[Dr. August Bones @Ausbones]

What CD4 count defines AIDS in an HIV-positive patient?

[Kiptembur @Kiptembur1]

@SyedHamadAhmad3 Management of non-pitting edema?

[Kiptembur @Kiptembur1]

@DocPriyamMD Very nice

[Dr. Priyam Bordoloi @DocPriyamMD]

It all comes down to a pharmacological concept called "Selective Toxicity"...the ability to kill the bug without killing the patient.

• Bacteria are independently living organisms. They have their own unique cellular machinery, like a cell wall, that human cells don't have. Because their biology is completely different from ours, we can easily design antibiotics that act like a targeted sniper. They destroy the bacteria while completely ignoring your healthy cells.

• Viruses are entirely different. They are obligate intracellular parasites. They don't have their own machinery to survive. When a virus enters your body, it physically invades your healthy cells and hijacks your own human DNA/RNA polymerases to multiply. Because the virus is using your cellular machinery, any drug designed to destroy it risks poisoning your own human cells in the process.

• "But wait, don't we have antivirals for things like HIV, Herpes or the Flu?"
Yes. But to make those, scientists spent decades and billions of dollars to find one unique viral enzyme (like reverse transcriptase or protease) that we could target without killing the host.

• For a mild, self-limiting infection, the only safe, highly targeted drug that can destroy the infected cells without wiping out the healthy ones is your own immune system.

👉Hi, I am Dr. Priyam. I break down complex medical science and advocate for Evidence-Based Medicine. Follow me for more clinical breakdowns.

[Kiptembur @Kiptembur1]

@uttdkola Mireles

[Kiptembur @Kiptembur1]

@adweramarvo @kh505043 This is new

[Kiptembur @Kiptembur1]

@Russia_X1 Yes 100

[Medical Notes @A25ma22]

WHO and CDC updates on Hantavirus on May 2026